“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says ...

"The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake," says James E. Lingeman, MD.

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter.

"With Aquablation, because of the real-time ultrasound image and the 3D animation that's created, you can see the actual dimensions and shape of the tunnel that's created before you even start the ...

A race coefficient improves 4Kscore calibration for Black men, enhancing prostate cancer risk assessment accuracy. Increasing diversity in clinical trials is crucial for more representative prostate ...

"There's a number of emerging modalities in the primary focal ablation space that are in trial at this time," says Kara L. Watts, MD. In this video, Kara L. Watts, MD, shares her predictions for ...

Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to ...

Studies reveal a connection between benign prostatic hyperplasia and erectile dysfunction, emphasizing the need for comprehensive patient management. Aquablation therapy receives a Category I CPT code ...

Nivolumab plus hyaluronidase-nvhy is approved for subcutaneous injection across all solid tumor indications previously approved for nivolumab. The CheckMate-67T trial showed subcutaneous nivolumab's ...

“These types of technologies can really make office urology much more efficient, which I think is very, very promising and one of the most promising areas in artificial intelligence,” says Chad ...

BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy. This condition requires alternative therapeutic strategies or radical ...

"As a result of the changes and the programmed phase-in of the changes, the cystoscopy code total RVU for the office setting will be 8% lower in 2025 than the current value," write Jonathan Rubenstein ...